Objective: To quantify the loss of pigmented neurons in the substantia nigra (SN) of autopsy-confirmed Parkinson disease (PD) and incidental Lewy body disease (ILBD) vs age-matched controls (C).
The loss of pigmented neurons in the substantia nigra (SN), also known as nigral neuronal loss (NNL), is one of the main pathologic features of Parkinson disease (PD). 1, 2 However, NNL is also observed in dementia with Lewy bodies (DLB), 3 in other neurodegenerative disorders, 4 and in clinically normal elders. 5 Another pathologic feature of PD/DLB is the presence of Lewy bodies (LB) and Lewy neurites/aggregates, referred to as Lewy-type synucleinopathy (LTS). [6] [7] [8] LTS is found in different regions of central, peripheral, and autonomic nervous systems, [9] [10] [11] [12] in extracerebral organs, 13 and in clinically normal elders at autopsy. 14 This is termed incidental LB disease (ILBD). 15 Whether ILBD is in the preclinical PD/DLB phase or is instead resistant to LTS and the disease will not develop is not established. [16] [17] [18] ILBD as a pathologic condition comes from studies describing an approximately 50% reduction in the concentrations of striatal dopaminergic markers. 19 A critical deficiency, however, has been the lack of unambiguous measurement of NNL in ILBD. 20, 21 We aimed to (1) count the number of nigral pigmented neurons in PD, ILBD, and controls (C) using unbiased stereology methods; (2) correlate NNL with nigral and extranigral amounts of LB, amyloid plaques (AP), neurofibrillary tangles (NFT), and motor and cognitive abnormalities before death; (3) look for possible mechanisms of cellular compensation in ILBD, i.e., increased cellular/subcellular volumes in nigral pigmented neurons of ILBD vs C; (4) test whether possible nigral neuronal volumetric changes could correlate with NNL, nigral and extranigral amounts of LB, anatomical distribution of LB, non-LTS copathologies, and motor and cognitive scores prior to death.
METHODS Participants enrolled from 1997 to 2013 in an ongoing longitudinal clinical-neuropathologic study, the Arizona Study of Aging and Neurodegenerative Disorders, with autopsies performed by the Banner Sun Health Research Institute Brain and Body Donation Program (www.brainandbodydonationprogram.org), were included. 22 Participants received annual movement disorder and cognitive assessments from time of entry to time of death, at which time an autopsy was performed. Three groups of participants were defined: 1. PD: autopsy-confirmed clinical diagnosis of idiopathic PD that included at least 2 of the 3 cardinal clinical signs of PD (resting tremor, muscular rigidity, bradykinesia) and brain positivity to LTS. 2. ILBD: autopsy-confirmed brain positivity to LTS without diagnosis of PD, DLB, or other neurodegenerative disease. 3. C: no brain positivity to LTS without diagnosis of PD, DLB, or other neurodegenerative disease.
A total of 18 brains were obtained, 6 per group: 6 PD, 6 ILBD, and 6 C.
Standard protocol approvals, registrations, and patient consents. All participants signed a written informed consent approved by the Banner Sun Health Research Institute Institutional Review Board to use their medical data and donated body specimens for research purposes.
Clinical and pathologic data. For each participant, the following clinical and pathologic diagnoses were excluded: Alzheimer disease (AD), vascular dementia, DLB, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, hippocampal sclerosis, motor neuron disease, Pick disease, Huntington disease, and frontotemporal lobar dementia with TDP-43 proteinopathy. Data on clinical and pathologic diagnoses, age at death, sex, race, cause of death, postmortem interval (PMI), brain weight (BW), and APOE genotype were available.
For each examined case, LB, AP, and NFT densities were available. LB densities (phosphorylated a-synuclein immunohistochemistry) were measured in SN, locus ceruleus (LC), olfactory bulb, brainstem at level of the IX and X cranial nerve, amygdala, and transentorhinal, cingulate, temporal, parietal, and frontal cortex. AP and NFT densities were assessed in frontal, temporal, parietal, and entorhinal cortex, and CA1 region of the hippocampus. The staging for each type of pathology was performed according to the Unified Staging System for Lewy Body Disorders (for LTS), 7 Consortium to Establish a Registry for Alzheimer's Disease criteria (for AP), 23 and NFT-Braak system (for NFT). 24 Data on depigmentation of SN, 25 vascular pathologies, infarct volumes, and cerebral amyloid angiopathy (CAA) were also available.
As documentation for the motor and cognitive status before death, the following data were available: Unified Parkinson's Disease Rating Scale (UPDRS)-motor scale (off medication), 26 Hoehn & Yahr (H&Y) stage, 27 time interval between last UPDRS-motor scale and death, time interval between last Mini-Mental State Examination (MMSE) 28 and death, cognitive impairment assessment (i.e., cognitively normal, mild cognitive impairment, or dementia), and levels of probability that dementia, if present, was due to AD pathology, as based on National Institute on Aging (NIA)-Reagan criteria. 29 Neuropathologic material and stereology methods. Eighteen sets of 40-mm-thick serially cut sections (1 every 24 from the entire SN) for each participant was received at the Neuropathology Research Labs, Biomedical Research Institute of New Jersey (BRInj). Histologic and staining procedures, stereologic protocols and measurements, and statistical analyses were performed at BRInj.
Each 40-mm-thick section was stained with a 1.0% solution of cresyl violet (CV) and used for the unbiased neuronal counting and volumetric measurements. Each section was randomly coded by an investigator blinded for the clinical and pathologic diagnoses (M.G.-E.) prior to any stereologic measurements, which were performed by a second clinical and pathologic diagnoses-blinded independent investigator (D.I.). Each section included both anatomical regions of SN: the pars compacta and pars reticulata.
We applied the following histologic criteria for neuronal counting:
1. Inclusion of any neuron, of any size, which contained neuromelanin detected by CV stain, within the marked SN anatomical contours.
Exclusion of all non-neuronal cells within the marked ana-
tomical SN contours, such as macrophages.
We applied the following adjunctive criteria for neuronal volumetric measurements:
1. Individuation of a well-defined non-neuromelanin-covered nucleolus for each randomly sampled nigral pigmented neuron. 2. Establishing the nucleolus as the only and constant point of spatial reference for any volumetric measurement (cell body, nucleus, and nucleolus) in each randomly sampled nigral pigmented neuron.
Measurements were performed using Stereo-Investigator system, version 10.0 (MBF Bioscience, Williston, VT). The sampling grid area was 500 3 500 mm, with a counting frame of 40 3 40 mm, disector height of 25 mm, and guard zones of 62 mm. The total number of CV-stained nigral pigmented neurons was estimated using the Optical Fractionator probe. 30 The oneside SN neuronal counting was doubled to obtain estimation of the total neuronal population in SN (assuming no pathologic/ cellular asymmetry between SN sides in PD, ILBD, and C).
Volumetric measurements were performed using the Nucleator probe. Cell body, nuclear, and nucleolar volumes of each nigral pigmented neuron were measured by placing 6 rays automatically centered on the nucleolus and randomly intersecting the cell membrane of each single randomly sampled pigmented neuron (figure 1). All volumetric measurements were performed employing a 1003 oil-immersion objective.
Statistical analyses. Analyses of variance (ANOVAs) were performed to detect group differences for mean age at death, PMI, BW, last MMSE and UPDRS-motor (off medication) scores, time intervals between last MMSE/UPDRS scores and death, and H&Y scores.
Before statistical analyses for each type of measurement (neuronal counting, cell body, nuclear and nucleolar volume), a series of Kolmogorov-Smirnov tests were performed. Kolmogorov-Smirnov tests confirmed that all data were normally distributed. ANOVAs were followed by 2 post hoc analyses: Tukey and Bonferroni tests for multiple comparisons. Adjustments for multiple comparisons established the statistical significance at p # 0.01.
Correlation analyses were performed between neuronal counting and nigral LB, extranigral LB (LC, olfactory bulb, brainstem at level of the IX and X cranial nerves, amygdala, and transentorhinal, cingulate, temporal, parietal, and frontal cortex), AP, NFT, mean cell body, nuclear and nucleolar volume, last MMSE/ UPDRS-motor scores, and H&Y stages for all groups.
RESULTS Data on demographics, clinical and pathologic diagnoses, cause of death, PMI, BW, APOE genotype, motor (UPDRS-motor and H&Y) scores, cognitive (MMSE, cognitive impairment, NIA-Reagan) scores, and their interval time to death are summarized in table 1. As for the mean age at death, PD and ILBD did not differ with respect to C, while PD differed vs ILBD, with the ILBD group being older. These findings substantiated the comparability of the mean age at death between ILBD and C, and reduced possible confounding effects due to aging 31 on the NNL measured in ILBD. No differences were observed for the mean PMI and BW across all 3 groups. Table 2 summarizes the main neuropathologic findings. AP and NFT densities scores showed a substantial comparability across PD, ILBD, and C. SN depigmentation was more severe in PD compared to ILBD and C. The total brain infarct volume was higher in ILBD compared to PD and C. CAA was higher in PD vs ILBD and C.
As for the cognitive status before death and interval time between last motor/cognitive evaluation and death, no differences were found across the 3 groups. The mean last MMSE scores did not differ across groups, while UPDRS-motor scores (off medication) and modified H&Y stage were higher in PD vs ILBD and C. The PD group had 2 low cases and 1 intermediate case as for the probability of dementia due to AD pathology based on NIA-Reagan criteria. There were no statistical differences across groups for APOE allelic frequencies.
Stereologic findings. Marked NNL was found in PD and ILBD vs C (p , 0.0001). The mean 6 SD neuronal count was 120,015 6 41,051 for PD, 402,045 6 199,163 for ILBD, and 664,308 6 103,541 for C. In PD and ILBD, the nigral neuronal counting was, respectively, 82% and 40% lower than C (figure 1). ANOVAs did not show differences for the mean nigral cell body volume between ILBD and C. Moreover, while the mean cell body, nuclear, and nucleolar volumes were lower (as for a possible subjacent atrophic process) in PD vs ILBD and C (p , 0.0001), the mean nuclear and nucleolar volumes were lower in both PD and ILBD vs C (p , 0.0001). These quantitative volumetric measurements seem to exclude cellular compensatory phenomena, for example a neuronal hypertrophy, in nigral pigmented neurons of ILBD in comparison to C.
The PD group showed correlations between NNL and LB in extranigral regions of the brain, such as olfactory bulb, cingulate, temporal, and parietal cortex. In the ILBD group, by contrast, no correlations were found between NNL and LB in any examined brain region. Furthermore, in both PD and ILBD groups, there were no correlations between NNL and AP or NFT densities, infarct volumes, and CAA.
In the ILBD group, correlations between mean cell body/nucleolar volume and LTS were found in amygdala and transentorhinal cortex, while in the PD group those correlations were found only in transentorhinal, cingulate, and temporal cortex.
No correlations were found in the ILBD or PD group between NNL and neuronal volumes, AP, and NFT densities; the only exception was found in the PD group, where the mean cell body volume and AP densities were correlated in the frontal cortex. No correlations were found between NNL and last UPDRS-motor scores and H&Y stages in either PD or ILBD. Table 3 shows the single correlation values (Pearson r) among neuronal counting, mean cell body, nuclear, and nucleolar volume with LB, AP, and NFT densities for each assessed brain region. Figure 1 shows histograms for the estimated neuronal counting, mean cell body, nuclear, and nucleolar volumes of nigral pigmented neurons in PD, ILBD, and C. Figure 2 shows graphic relationships between NNL and their cell body volume, as between NNL and the LB sum densities in PD, ILBD, and C. Table e-1 on the Neurology ® Web site at Neurology.org, upper part, using a color-based coding system, describes the neuroanatomical distribution of LB pathology and its level of severity (none, mild, moderate, severe, very severe) across all groups. Table e-1, lower part, using a color-based coding system as well, describes the presence (yes) or the absence (no) of LB across all examined cerebral regions.
DISCUSSION Whether ILBD participants represent individuals who did not live long enough to develop PD or DLB, or instead they represent a condition of asymptomaticity and neuronal resistance to LTS and NNL, are 2 important pathophysiologic questions whose answers could imply, potentially, new ways on how to prevent, halt, or at least delay the progression of ILBD in PD or DLB. So far, it is not possible to definitely establish if PD and DLB are manifestations of different pathogenetic processes or if they are expressions of an identical pathologic process related to the specific characteristics of neuronal vulnerability in different participants, to possible compensatory mechanisms, or to peculiar anatomical characteristics of the neuronal circuits involved in the initial formation and spreading of LTS. 8, 32 Since both PD and DLB are diseases pathologically characterized by nigral accumulation of LB/LTS, and both could have ILBD as a preclinical phase, it was of crucial importance to establish whether there is an unequivocal NNL in ILBD, and if so, which could be its severity in comparison to PD and age-matched C. Our quantitative stereologic findings show NNL in ILBD participants in comparison to age-matched control elders. In addition, although we found correlations between some extranigral LB burdens and NNL, no correlation was found within the SN. One of the possible explanations for this may be that the high rate of cell death and subsequent phagocytosis of LB/LTS could obscure the direct relationship between NNL and LB/LTS. A more drastic hypothesis could imply that LB/LTS is not related to NNL at all and that the observed NNL could just be an aging-related phenomenon coexisting with a simultaneous independent process of LB/LTS formation and accumulation. This latter pathologic process could be induced by triggers that are different from those causing NNL. A further hypothesis could be that the formation of LB/LTS begins, or is inducible, only in some specific and more vulnerable extranigral cerebral areas (i.e., olfactory bulb? Nucleus motor dorsal vagus? Others?) from which LB/LTS pathology can be spread across multiple extranigral regions of the brain as well as to the SN. This hypothesis could explain the appearance of initial dystrophic/atrophic phenomena and consequent NNL as a progressive spectrum of degenerative cellular phenomena related to the synucleinopathic process and its progression. This hypothesis, moreover, fits well with the prion-like theory recently proposed to better explain the spreading of a-synucleinopathies across preferential neuronal circuits and anatomical directions. 33 Our findings show that in the nigral pigmented neurons of ILBD brains, subcellular abnormalities, such as nuclear and nucleolar decreased volumes (possible signals of neuronal atrophy), are indeed present in the context of an already significant NNL, and importantly, in the absence of a clinically relevant motor and cognitive symptomatology. This supports the hypothesis that ILBD is a preclinical phase of PD/DLB. Some previous nonstereologic investigations supported this hypothesis. 34 However, those studies 34 could not detect a significant NNL in ILBD compared to controls. Here, using unbiased stereology methods, we show that a significant neuronal loss is actually already present in the SN of ILBD in comparison to C.
Our measurements show that a 40% reduction of NNL in ILBD vs C is still compatible with an absence of clinically significant motor or cognitive symptoms. This suggests that although some resistive or compensatory mechanisms may not be present at cellular level, inside or outside the SN, they could actually be activated at neurotrasmettitorial, receptorial, synaptic, or even at molecular level.
Further, it could be hypothesized that the total number of pigmented neurons in the SN of a normally developed adult brain could actually exceed the minimal number of neurons required for a normal functioning of SN. This "nigral neuronal reserve" could explain why, for example, in clinically normal and LTS-negative elders the presence of NNL is not always or mandatorily associated with clinically relevant motor or cognitive symptoms.
PD and ILBD, however, and although with different amounts, often have overlapping LTS cerebral distributions (table 2 and table e-1). So important questions remain open: How might ILBD evolve, if it evolves, towards PD or DLB? Is this just a question of time? If ILBD represents a preclinical phase subjacent to an identical pathogenetic process (a-synucleinopathy) for both PD and DLB, is there a different neuronal vulnerability? Possible compensatory or different vulnerability properties, as well as protective factors, should be taken into account since aging per se does not seem to play a major additive role in causing NNL in ILBD. In this study, the ILBD group was older than the PD group, and previous studies show comparable results. 9, 20 It is also important to consider that specific genotypes (i.e., LRRK2 gene and its variants) as well as environmental cofactors could accelerate or decelerate the progression/deposition of LB and consequent NNL. 35 Our study presents some caveats: the relatively small sample size, the unavailability of quantitative measurements (i.e., using stereologic tools) of the various brain copathologies (LTS, AP, NFT) present in those individuals, and positive UPDRS scores in some ILBD and C. Although positive UPDRS scores in older participants are not rarely observed due to various medical conditions, more sophisticated clinical assessments should be performed to exclude more subtle extrapyramidal signs.
Larger autopsy quantitative stereology-based studies need to confirm our novel findings. We support that ILBD is a genuine pathologic status, and that it can represent a preclinical phase of PD/DLB, since we found significant NNL in those brains in comparison to C. Furthermore, the lack of hypertrophy in nigral pigmented neurons does not support the presence of cellular compensatory mechanisms in the SN of ILBD brains. Moreover, cortical AP and NFT densities, as infarct volumes and CAA, do not seem to have a major contributing role in determining NNL.
